Insider Selling: SiBone (NASDAQ:SIBN) Director Sells 20,000 Shares of Stock

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 20,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $20.89, for a total value of $417,800.00. Following the completion of the sale, the director directly owned 16,057 shares of the company’s stock, valued at approximately $335,430.73. This represents a 55.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

SiBone Stock Up 5.0%

NASDAQ SIBN traded up $1.18 during trading on Wednesday, reaching $24.95. 2,186,969 shares of the company’s stock were exchanged, compared to its average volume of 637,019. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $25.92. The company’s fifty day simple moving average is $19.50 and its 200-day simple moving average is $16.48. The firm has a market capitalization of $1.11 billion, a PE ratio of -80.48 and a beta of 0.64.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. The company had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative return on equity of 7.62% and a negative net margin of 6.20%. Sell-side analysts predict that SiBone will post -0.40 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. First Light Asset Management LLC lifted its stake in shares of SiBone by 51.8% in the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock valued at $132,649,000 after purchasing an additional 2,774,795 shares during the last quarter. Granahan Investment Management LLC boosted its holdings in SiBone by 97.6% in the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after purchasing an additional 858,942 shares in the last quarter. Paradigm Capital Management Inc. NY increased its position in SiBone by 113.3% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after buying an additional 598,300 shares during the last quarter. Renaissance Technologies LLC increased its position in SiBone by 101.6% during the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock worth $5,969,000 after buying an additional 238,219 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in SiBone by 41.8% during the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock valued at $7,816,000 after buying an additional 182,465 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone News Roundup

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Q3 results beat estimates. SI-BONE reported a loss of $0.08 per share, smaller than the $0.13 loss analysts expected, while revenue of $55.7 million narrowly topped the $55.3 million estimate. The quarterly loss also improved from $0.11 per share a year earlier. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: UBS raised its price target and kept a Buy rating. UBS lifted its target from $25 to $26, implying about 4.3% upside from the cited $24.92 share price. UBS price-target update
• Neutral Sentiment: 2026 revenue guidance was essentially in line. SI-BONE forecast revenue of $231 million to $233 million, bracketing the $232.2 million consensus estimate. TD Cowen raised its target from $20 to $23 and reiterated Buy, although that target is below the cited current share price. TD Cowen analyst update
• Negative Sentiment: Two executives sold shares. SVP Michael Pisetsky sold 29,665 shares for about $656,000, reducing his holdings by 15.28%; insider Anshul Maheshwari sold 3,738 shares for about $84,000. Such sales can weigh on sentiment, though both retained substantial holdings. SI-BONE insider sales

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SIBN shares. UBS Group increased their target price on shares of SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday. Needham & Company LLC dropped their price target on shares of SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Tuesday. TD Cowen increased their price objective on SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Tuesday. Citigroup reissued a “market outperform” rating on shares of SiBone in a research report on Tuesday. Finally, Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.